Details
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | e202303730 |
| Fachzeitschrift | CHEMISTRYSELECT |
| Jahrgang | 8 |
| Ausgabenummer | 46 |
| Publikationsstatus | Veröffentlicht - 11 Dez. 2023 |
| Extern publiziert | Ja |
Abstract
Despite the continued efforts and advancements in anti-cancer drug discovery, cancer is still considered as one of the leading causes of mortality globally. Hence, the discovery of novel chemotherapeutic agents that displayed a prominent effect against cancer is a pressing need. In this study, an expeditious cascade was used to access a pilot library of indolopyrazine fused to imidazole and pyrimidinone heterocyclic scaffolds. The synthetic strategy utilized a cascade reaction that combined Mannich with aza-Michael addition reactions followed by coupling with a variety of amines. Phenotypic screening of the developed library against HCT116 colon and MCF-7 breast cancer cell lines identified chemotypes that formed the basis for hit-to-lead development of anti-cancer agents. The intriguing architecture and scope of functional variability of these types of pentacyclic molecules made them appropriate motifs for the development of lead drug candidates.
ASJC Scopus Sachgebiete
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: CHEMISTRYSELECT, Jahrgang 8, Nr. 46, e202303730, 11.12.2023.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Divergent Strategy for the Synthesis of Indolopyrazines Fused to Benzopyrimidinones and Benzimidazoles: Identification of Antiproliferative Molecules
AU - Alkubaisi, Bilal O.
AU - Sebastian, Anusha
AU - Bauer, Maximilian
AU - Sultan, Shaista
AU - El‐Awady, Raafat
AU - Wehbe, Ayeh
AU - Yassin, Mariam
AU - Vunnam, Srinivasulu
AU - El‐Gamal, Mohammed I.
AU - Al‐Tel, Taleb H.
N1 - Publisher Copyright: © 2023 Wiley-VCH GmbH.
PY - 2023/12/11
Y1 - 2023/12/11
N2 - Despite the continued efforts and advancements in anti-cancer drug discovery, cancer is still considered as one of the leading causes of mortality globally. Hence, the discovery of novel chemotherapeutic agents that displayed a prominent effect against cancer is a pressing need. In this study, an expeditious cascade was used to access a pilot library of indolopyrazine fused to imidazole and pyrimidinone heterocyclic scaffolds. The synthetic strategy utilized a cascade reaction that combined Mannich with aza-Michael addition reactions followed by coupling with a variety of amines. Phenotypic screening of the developed library against HCT116 colon and MCF-7 breast cancer cell lines identified chemotypes that formed the basis for hit-to-lead development of anti-cancer agents. The intriguing architecture and scope of functional variability of these types of pentacyclic molecules made them appropriate motifs for the development of lead drug candidates.
AB - Despite the continued efforts and advancements in anti-cancer drug discovery, cancer is still considered as one of the leading causes of mortality globally. Hence, the discovery of novel chemotherapeutic agents that displayed a prominent effect against cancer is a pressing need. In this study, an expeditious cascade was used to access a pilot library of indolopyrazine fused to imidazole and pyrimidinone heterocyclic scaffolds. The synthetic strategy utilized a cascade reaction that combined Mannich with aza-Michael addition reactions followed by coupling with a variety of amines. Phenotypic screening of the developed library against HCT116 colon and MCF-7 breast cancer cell lines identified chemotypes that formed the basis for hit-to-lead development of anti-cancer agents. The intriguing architecture and scope of functional variability of these types of pentacyclic molecules made them appropriate motifs for the development of lead drug candidates.
KW - Anticancer
KW - Aza-Michael addition
KW - Evodiamine
KW - Indolopyrazines
KW - Mannich reaction
UR - http://www.scopus.com/inward/record.url?scp=85179347669&partnerID=8YFLogxK
U2 - 10.1002/slct.202303730
DO - 10.1002/slct.202303730
M3 - Article
VL - 8
JO - CHEMISTRYSELECT
JF - CHEMISTRYSELECT
SN - 2365-6549
IS - 46
M1 - e202303730
ER -